An elderly couple with COVID-19 pneumonia treated in Singapore: contrasting clinical course and management

Wong, Serre-Yu; Leong, Keng Hong; Ng, Kheng Siang; Tan, Seng Hoe; Lo, Pau Lin Constance; Chan, KP

doi:10.11622/smedj.2020064

Cited by 5 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В настоящее время многочисленные данные, касающиеся эффективности и безопасности ТЦЗ при COVID-19, отражены в серии клинических наблюдений, в открытых исследованиях, РКИ и метаанализах. Большинство клинических случаев, которые были опубликованы еще в самом начале пандемии, демонстрируют высокую эффективность 1-3 инфузий ТЦЗ (8 мг/кг) у пациентов с тяжелым и критическим течением COVID-19 [31][32][33][34][35]. Вместе с тем существуют клинические наблюдения, которые свидетельствуют о сохранении критического состояния больных или наступлении летального исхода, несмотря на терапию ТЦЗ [36,37].…”

Section: ил-6 при Covid-19unclassified

Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19

Muravyeva

Белов

2022

Medicinskij sovet

View full text Add to dashboard Cite

The key role in the development of chronic autoimmune inflammation is played by pro-inflammatory cytokines, in particular, interleukin 6 (IL-6). The introduction into clinical practice of monoclonal antibodies inhibiting IL-6 is a significant event in rheumatology and is currently considered as a promising direction in the treatment of immuno-inflammatory rheumatic diseases. The first inhibitor of IL-6 (IL-6), which entered the practice of rheumatologists, was tocilizumab (TCZ), the second – sarilumab (SAR). Numerous studies have shown the high effectiveness of iIL-6: the use of drugs leads to a rapid decrease in the clinical manifestations of rheumatoid arthritis (RA) and a decrease in laboratory signs of inflammation, contributing to the achievement of low activity or remission, improves the quality of life of patients, and also slows down the X-ray progression of the disease. At the same time, iIL-6 has a satisfactory safety profile. The universal problem of our time – the pandemic of a new coronavirus infection – has led to attempts to use IL-6 in patients with severe and critical disease, since IL-6 plays an important role in the pathogenesis of COVID-19, which is confirmed by the results of numerous studies. However, data on the efficacy and safety of these drugs in COVID-19 are contradictory, which requires conducting larger-scale controlled studies. This review examines the issues of the effectiveness and safety of TCZ and SAR in rheumatological patients and in patients with COVID-19. The review is illustrated with examples from real clinical practice.

show abstract

Section: ил-6 при Covid-19unclassified

Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19

Muravyeva

Белов

2022

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

“…Various aspects of the molecular pathology of COVID-19 [277][278][279][280][281][282][283] were studied as well, such as the T-cell response [277] and the viral spike protein [278]. There were a few articles about general COVID-19 pathology [284][285][286][287], which included combinations of topics from the above sub-categories. Another few were about co-infection with other pathogens, such as the human immunodeficiency virus (HIV) [288,289] and mycoplasma pneumoniae [290].…”

Section: Covid-19 Pathology (94 Articles)mentioning

confidence: 99%

One Year on: An Overview of Singapore’s Response to COVID-19—What We Did, How We Fared, How We Can Move Forward

Anand

Shuy

Lee³

et al. 2021

IJERPH

View full text Add to dashboard Cite

Background—One year has passed since the first COVID-19 case in Singapore. This scoping review commemorates Singaporean researchers that have expanded the knowledge on this novel virus. We aim to provide an overview of healthcare-related articles published in peer-reviewed journals, authored by the Singapore research community about COVID-19 during the first year of the pandemic. Methods—This was reported using the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) protocol. It included healthcare-related articles about COVID-19 published between 23 January 2020 and 22 January 2021 with a Singapore-affiliated author. MEDLINE, Embase, Scopus, Web of Science, CINAHL, PsycINFO, Google Scholar, and local journals were searched. The articles were screened independently by two reviewers. Results—The review included 504 articles. Most of the articles narrated the changes to hospital practice (210), while articles on COVID-19 pathology (94) formed most of the non-narrative papers. Publications on public health (61) and the indirect impacts to clinical outcomes (45) were other major themes explored by the research community. The remaining articles detailed the psychological impact of the pandemic (35), adaptations of medical education (30), and narratives of events (14). Conclusion—Amidst a resurgence of community cases involving variant COVID-19 strains, the resources from the research community will provide valuable guidance to navigate these uncertain times.

show abstract

“…They may present with an entire spectrum of disease, from mild acute respiratory symptoms to severe pneumonia requiring intensive care. (8) On imaging, plain film and computed tomography appearances are also highly variable. (9,10) More recently, severe cardiovascular complications such as thrombosis, myocardial injury and myocarditis have been described.…”

Section: Clinical Perspectivesmentioning

confidence: 99%

COVID-19: local lessons from a global pandemic

Ngiam¹,

Tham²,

Vasoo³

et al. 2020

smedj

View full text Add to dashboard Cite

An elderly couple with COVID-19 pneumonia treated in Singapore: contrasting clinical course and management

Cited by 5 publications

References 14 publications

Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19

Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19

One Year on: An Overview of Singapore’s Response to COVID-19—What We Did, How We Fared, How We Can Move Forward

COVID-19: local lessons from a global pandemic

Contact Info

Product

Resources

About